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a  b  s  t  r  a  c  t
Empirical antifungal therapy is most often given to patients with leukemia. However break-
through fungal infections under antifungal therapy are not uncommon. Four children, with
hematologic malignant disease developed mycotic breakthrough infections while on empir-
ical  caspofungin treatment for a median of 14 (range 11–19) days. Trichosporon asahii was
detected in the blood culture of two patients and Geotrichum capitatum in the other two (one
patient also had positive cerebrospinal ﬂuid culture). Because the patients’ clinical situation
worsened, voriconazole was empirically added for two patients three and ﬁve days before
the  agent was detected. The ﬁrst sterile blood culture was obtained 3–7 days of voricona-
zole  treatment. All patients reached clear cultures but one patient died. One patient with
central nervous system infection with G. capitatum had severe neurological sequelae. Verysevere fungal infections can occur during empirical caspofungin therapy. Therefore, patients
should be followed closely.
© 2015 Elsevier Editora Ltda. All rights reserved.
severe immuncompromise. The outcome of disseminated Tri-ntroductionnvasive fungal infections (IFIs) have signiﬁcant impact on
eukemia patients’ survival. Although antifungal drugs are
mpirically given to most of the patients, breakthrough fungal
nfections are not uncommon.1–5
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plication of neutropenia and other conditions associated withBayrakli-Izmir, Turkey.
chosporon infection is most often poor, and the fatality rate is
over 70%.3,6–9 Recently the genus Trichosporon has been taxo-
nomically revised. Generally, two species have been associated
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with IFIs in humans: Trichosporon beigelii and Trichosporon cap-
itatum.  T. capitatum has now been reclassiﬁed as Geotrichum
capitatum or Blastoschizomyces capitatus. T. beigelii now corre-
sponds to six different species. Invasive Trichosporon infections
are due to T. asahii in most cases.6,7
The increased use of echinocandins leads to signiﬁcant
selective pressure, which favors opportunistic fungi, that
are resistant to these agents. Disseminated trichosporonosis
has been reported in immunocompromised patients under
echinocandin therapy.3,4,7–14 Breakthrough trichosporonosis




A 16-year-old girl with acquired very severe aplastic anemia
(vSAA) received immunosuppressive therapy (IST) consisting
of rabbit anti-thymocyte globuline (ATG), cyclosporine A, gran-
ulocyte colony stimulating factor (GCSF), and prednisolone
after replacement of central venous catheter (CVC). She had
no hematological response to IST. Six months after diagnosis
of vSAA and 44 days after initiation of IST, the patient was
still on regular platelet and erythrocyte transfusion, had very
severe neutropenia, and developed febrile neutropenia (FN).
On 6th day of FN caspofungin was initiated as empirical anti-
fungal therapy. She developed maculopapular rash on 11th
day of caspofungin treatment. Her clinical condition wors-
ened. The patient developed hepatosplenomegaly (HSM) and
severe respiratory distress. She was admitted to the pediatric
intensive care unit (PICU), and required mechanical venti-
lation (MV). Blood cultures taken 15 days after initiation of
caspofungin revealed yeast, later identiﬁed as T. asahii. Table 1
shows the minimal inhibitory concentration (MIC) of antifun-
gals. Voriconazole (VCZ) was started. Although blood cultures
were negative seven days after initiation of VCZ, the patient
clinical condition did not improve. Fever, HSM, respiratory fail-
ure, and pancytopenia persisted. She developed renal failure
and expired 13 days after clearing blood culture.
Case  2
A 5-year-old girl with pre-B cell acute lymphoblastic leukemia
(ALL) was included in the standard risk (SR) arm of ALL IC-BFM
2002 treatment protocol. A CVC was inserted. On 42nd day
of treatment (day 0), she developed FN (ANC was 12 mm−3)
and empirical caspofungin was started on day 5 thereafter.
She presented diarrhea and feeding intolerance. Leukemia
treatment was discontinued on day 21 (63rd day of induc-
tion therapy). Disseminated maculopapular lesions appeared
and she developed sepsis. VCZ (4 mg/kg every 12 h) was added
to treatment empirically on day 26 and three days later she
developed severe respiratory distress. CVC was removed. The
patient was transferred to PICU, requiring intubation and MV.
Cultures of three blood samples obtained 19 days after initia-
tion of caspofungin treatment and three days before starting
VCZ yielded yeasts, later identiﬁed as T. asahii.  The agent was
sensitive to VCZ (Table 1). Although all blood cultures became 1 5;1  9(5):549–552
negative after four days of VCZ therapy, she developed sec-
ondary hemophagocytosis (HLH) and was treated according to
HLH 2004 protocol for two weeks. After resolution of clinical
and laboratory ﬁndings related to secondary HLH, she con-
tinued to receive ALL IC-BFM 2002 chemotherapy protocol.
Secondary antifungal prophylaxis was administered with VCZ
for six months and she completed the chemotherapy protocol
without reactivation of T. asahii.
Case  3
A 2.5-year-old boy with pre-B cell ALL was included in HR arm
of ALL IC-BFM 2002 treatment protocol. A port catheter was
inserted. On 22nd day of treatment (day 0), he developed FN
(ANC was 12 mm−3). Empirical caspofungin was started on
day 4. He could not achieve hematologic remission by day
15 (33rd day of treatment protocol) and on day 17, VCZ was
added as a second antifungal agent due to worsening clinical
condition. Serum galactomannan test was found to be posi-
tive. Blood samples for culture were taken on day 18 (14th day
of Caspofungin treatment and 1st day of voriconazole treat-
ment) yielded yeasts, later identiﬁed as G. capitatum.  On day
19, caspofungin was stopped and liposomal amphotericin B
(LiAmB) was started at the dose of 5 mg/kg, then the dose was
increased up to 10 mg/kg/day. Blood cultures were negative on
day 23, eight days after VCZ initiation and four days of LiAmB.
CVC was removed and culture of the catheter tip yielded the
same fungi. Antifungal therapy was continued with combined
antifungals for three months without reactivation of IFI.
Case  4
A 2.5-year-old girl with pre-B cell ALL was included in HR
arm of ALL IC-BFM 2002 treatment protocol after insertion
of CVC. She had central nervous system involvement. On
the 4th day (day 0) of treatment, she developed FN (ANC
was 104 mm−3). Empirical caspofungin was started on day
8. Fever disappeared 12 days thereafter. A port catheter was
inserted on day 15. While she was still on caspofungin treat-
ment she again developed febrile neutropenia on day 17. On
day 21, abdominal computerized tomography showed multi-
ple spleen and kidney hypodense nodular lesions with less
than 1 cm diameter. On day 25 she developed severe agitation,
and cranial magnetic resonance imaging (MRI) showed mul-
tiple diffuse cortical and subcortical lesions. On day 29 (33rd
day of treatment), bone marrow aspiration revealed hemato-
logical remission, and intrathecal treatment was given after
cerebrospinal ﬂuid (CSF) sample was taken according to the
protocol. Two days later, on day 31, she developed status
epilepticus. She was then transferred to PICU and required MV.
Serum galactomannan antigen test was found to be weak pos-
itive. Empirical VCZ (8 mg/kg/day) was added. On day 32, CSF
culture yielded yeasts, later identiﬁed as G. capitatum. Anti-
fungal susceptibility is shown in Table 1. Caspofungin was
stopped and LiAmB was started at the dose of 5 mg/kg/day.
Catheter tip, peripheral blood, and urine cultures yielded
G. capitatum.  Port catheter was removed. After four days of
LiAmB and ﬁve days of VCZ all blood cultures were nega-
tive. However, cranial MRI  showed progressive encephalitis
on day 40. CSF reservoir was inserted and CSF samples from
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Table 1 – Minimum inhibitory concentration (g/mL) of antifungal drugs displayed against isolate.
Patient no. Isolate (isolation site) Amp B Fluconazole Itraconazole Voriconazole Posaconazole Caspofungin Amidalafungin
1 T. asahii
(Blood)




0.032  4 0.064 0.064 0.125 >32 32
3 G. capitatum
(Blood)
0.032  4 0.50 0.125 >32 6
4 T. asahii
(Blood)
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he reservoir yielded G. capitatum.  Intrathecal amphotericin
 at the dose of 0.25 mg/day was given. The ﬁrst sterile CSF
ulture was achieved after 16 days of intravenous VCZ, 15
ays of LiAmB, and four days of intrathecal amphotericin B.
espite antibiotic and antifungal therapies, fever persisted.
ranial MRI  showed progressive encephalitis, external ventri-
ular drainage was inserted and intrathecal AmB was given for
1 days. She weaned from MV  78 days thereafter. She contin-
ed to receive combined antifungal therapy for 267 days but
eveloped severe neurological sequelae.
iscussion
FI is a signiﬁcant cause of morbidity and mortality among
atients with hematologic malignancies. Empirical antifun-
al therapy is highly recommended after four days of FN in
his population. Caspofungin and amphotericin B are the sug-
ested antifungal agents for empirical threraoy.15
Invasive infections caused by Trichosporon species are rare
ut potentially fatal complications of the immunosuppression
ssociated with treatment of cancer.3,7 Among Trichosporon
pecies, G. capitatum has emerged as a rare fungal pathogen
n recent years, particularly in severely immunocompromised
osts. IFI caused by this agent is often characterized by a mul-
iorgan involvement with a fatal course despite antifungal
herapy.16–19 The incidence of G. capitatum infection among
atients with leukemia was found to be 0.5% with a crude
ortality rate of 55%. Several studies collecting cases of G.
apitatum infections in hematological patients have showed a
0-day attributable mortality ranging from 40% to 75%.
Caspofungin has a good fungistatic and fungicidal activity
gainst a variety of yeasts, but does not show activity against
. capitatum and the other fungi of Trichosporon species.2–5,17
The presented four patients with hematologic malignant
isease developed severe fungal breakthrough infections with
are causative agents. All of the patients had a CVC, very severe
eutropenia, and were initially treated with broad-spectrum
ntibiotics. Since fever and severe neutropenia persisted in all
atients, empirical changes in antibiotic combinations were
mplemented despite no agent being isolated in the cultures.
t a median of ﬁve days (range 4–8 days) of FN, caspofungin
as started in all these patients, who had fever and hep-
tosplenomegaly. Cutaneous maculopapular rash was seen in
wo patients. One had status epilepticus and multiple cerebral
bscesses at presentation of mycotic infection. Three of these0.125 >32 12
patients required intubation and MV, and were admitted at the
PICU.
Because the patients’ clinical situation worsened, in two
patients VCZ was added to antifungal therapy empirically one
and three days before the agent was detected.
Echinocandins alone have little to no activity against Tri-
chosporon spp. and are not recommended for trichosporonosis
treatment.2–5 In the literature almost all IFIs caused by T. asahii
or G. capitatum occurred as breakthrough infection in patients
who received antifungal therapy, especially echinocandins for
at least ﬁve to seven days.8–10
Fluconazole was used as the initial therapy in 85% of
19 patients with invasive trichosporonosis documented in
a single medical center in Taiwan, and the mortality rate
was 42%.9 Suzuki et al.10 recently evaluated the clinical and
therapeutic aspects of 33 cases of Trichosporon fungemia doc-
umented in patients with hematological malignancies. The
authors clearly demonstrated that survival was longer for
patients treated with an azole than for those treated with
other drugs. Triazoles seem to have better in vitro and in vivo
antifungal activity against Trichosporon spp. than ampho-
tericin B. VCZ also has excellent in vitro activity against
Trichosporon strains and may be useful for treating patients
with trichosporonosis.3,6
In conclusion, disseminated trichosporonosis and G. capi-
tatum infections have been increasingly reported worldwide.
Treatment with echinocandins should be accepted as a risk
factor in immunosuppressed patients, especially in institu-
tions where the infection had been detected before. Prognosis
is limited, and antifungal regimens containing triazoles
appear to be the best therapeutic approach.
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